222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2100004997 | 2021-07-01 | 2021-06-28 | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | PRIMARY MEMBRANOUS NEPHROPATHY | control group:Placebo 120mg orally intake twice a day;experimental group:Sinomenine 120mg orally intake twice a day; | Macau University of Science and Technology | NULL | Pending | 18 | 70 | Both | control group:80;experimental group:80; | Phase 4 | China |
| 2 | ChiCTR2100047996 | 2021-07-01 | 2021-06-28 | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | PRIMARY MEMBRANOUS NEPHROPATHY | experimental group:Sinomenine 120mg orally intake twice a day;control group:Placebo 120mg orally intake twice a day; | Macau University of Science and Technology | NULL | Pending | 18 | 70 | Both | experimental group:80;control group:80; | Phase 4 | China |